Compare Ecopetrol SA (EC) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecopetrol SA vs Summit Therapeutics Inc — how do they compare? Ecopetrol SA trades at $16.93 (market cap $33.11B), while Summit Therapeutics Inc trades at $17.38 (market cap $13.71B). The key difference: Ecopetrol SA is far larger — about 2.4× Summit Therapeutics Inc's market cap, and Ecopetrol SA pays a 3.83% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ecopetrol SA for 84 Days and Summit Therapeutics Inc for 16 Days on average.
| EC | SMMT | |
|---|---|---|
Market Cap | $33.11B | $13.71B |
Volume | 993,598 | 6,173,057 |
Sector | Energy | Health |
52-Week High | $18.26 | $26.38 |
52-Week Low | $8.61 | $12.43 |
Typical Hold Time | 84 Days | 16 Days |
Enterprise Value | $61.36B | $13.04B |
Dividend Yield | 3.83% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ecopetrol (EC) trades at $16.63, down 1.95% with bearish technical signals. The stock shows attractive valuation metrics with P/E of 7.99 and EV/EBITDA of 4.04, but faces declining revenue from $159.6B in 2022 to $119.7B in 2025. Recent management changes and board restructuring under Colombia's new government create uncertainty, while the company maintains solid profitability with 11.37% net margin and 17.67% ROE.
EC presents a mixed outlook with undervalued fundamentals against operational challenges. Investment opportunity lies in discounted valuation and potential stabilization under new leadership, but risks include persistent revenue decline, political interference, and negative cash flow trends. Analyst consensus remains cautious with 54.55% hold rating and $16.85 price target, slightly above current levels.
Summit Therapeutics (SMMT) trades at $17.95, up 3.7% with strong technical momentum and bullish analyst sentiment. The stock shows negative profitability metrics but benefits from AstraZeneca's $2 billion strategic investment and clinical collaborations. Recent news highlights positive clinical trial results for ivonescimab, driving investor optimism despite current financial losses.
The outlook remains speculative with significant upside potential based on analyst consensus targets averaging $29.33, though high valuation multiples and negative cash flows present substantial risk. Success of clinical trials and partnership execution will determine long-term value creation for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ecopetrol SA
Ecopetrol SA is a vertically integrated oil company with operations in Latin America and the United States Gulf Coast. Based out of Colombia, the company explores, develops, and conducts production activities in various countries. Ecopetrol works as the primary operator or partner in a joint venture, in a host of assets held onshore and offshore. Along with production, the company refines and markets crude oils and byproducts produced from its fields. Crude products are moved by Ecopetrol through a series of pipelines throughout Colombia, along with a network of third-party production centers and facilities.
Read more on EC →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
